Prognostic Impact of Different Iron Parameters In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 168-168
Author(s):  
Godwin Nosakhare Bazuave ◽  
Andreas S. Buser ◽  
Sabine Gerull ◽  
André Tichelli ◽  
Martin Stern

Abstract Abstract 168 Pre-transplant iron overload contributes to increased transplant related mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Serum ferritin is a useful marker to detect iron overload, and is strongly associated with survival rates after allogeneic HSCT. Ferritin is also elevated in patients with inflammatory conditions and may therefore lack specificity as a marker of iron overload. Other iron parameters such as the soluble transferrin receptor (which is not elevated during acute phase reactions), or transferrin saturation (which strongly correlates with non-transferrin bound iron causing tissue damage) might be superior as prognostic parameters. We retrospectively studied pre-transplant serum iron parameters (ferritin, transferrin, transferrin saturation, iron, soluble transferrin receptor [sTfR]) in 230 consecutive patients undergoing myeloablative allogeneic stem cell transplantation at our centre between 2002 and 2009. C-reactive protein (CRP) was measured as a marker for inflammatory diseases. Median age at transplant was 45 (range 17–70), 132 patients were male, 98 female. Diagnoses were ALL (n=43), AML (n=123), lymphoma (2=37), MPN (n=20), and non-malignant disorders (n=7). Conditioning was with Cy/TBI +/− VP 16 (n=109), BEAM/Fludarabine/TBI (n=29), BuCy (n=88), or other (n=4). All patients received pharmacological GvHD prophylaxis with CSA/MTX (n=201) or CSA/MMF (n=29). Median values of iron parameters were: ferritin 1342 ng/ml (range 7-7'260); transferrin 1.9 g/l (range 0.8–3.5); transferrin saturation 36% (range 4–106%); iron 18 μ mol/l (range 3–52); sTfR 3.2 mg/l (range 0.3–73). Interestingly, no significant correlation was found between ferritin and CRP (r=0.09, p=0.16). All iron parameters predicted survival, when patients were categorized into those with levels below or above the median. In Kaplan-Meier analysis, transferrin saturation showed the highest predictive power (5 year survival if below median 64±5%; if above median 32±5%; likelihood ratio [LR] 23.2, p<10e5, Figure 1). Ferritin, in comparison, had lower prognostic significance (survival 61±5% versus 39±5%, LR13.1, p=0.0003). The predictive power of sTfR was between that of ferritin and transferrin saturation (34±5% versus 65±5%, LR 20.2, p<10e5), whereas transferrin and iron fared markedly worse and were not further analyzed. In multivariate Cox models adjusted for diagnosis, disease stage, CRP, stem cell source, donor type, and year of transplant, hazard ratios with borderline significance were found for ferritin (HR 1.51, 95% CI 0.98–2.33, p=0.06) and sTfR (HR 1.50, 95% CI 0.96–2.34, p=0.07). In contrast, transferrin saturation retained clear prognostic significance (HR 1.90, 95% CI 1.23–2.94, p=0.004). Receiver operating characteristic curve analysis confirmed the superiority of transferrin saturation as a predictor of transplant outcome over a wide range of cutoff values (area under the curve for transferrin saturation 0.715, for ferritin 0.657, Figure 2). Iron overload strongly influences outcome of allogeneic stem cell transplantation. In this population of patients with a history of repeated red blood cell transfusions, serum ferritin levels were not significantly influenced by inflammatory states, as assessed by the lack of association with elevated CRP levels. Of the iron parameters studied, serum transferrin saturation had the highest predictive power in both univariate and multivariate models. Figure 1. Kaplan-Meier estimates of survival after allogeneic HSCT in patients stratified according to below- or above-median pre-transplant iron parameters and C-reactive protein Figure 1. Kaplan-Meier estimates of survival after allogeneic HSCT in patients stratified according to below- or above-median pre-transplant iron parameters and C-reactive protein Figure 2. Receiver operating characteristics (ROC) curve for pretransplant ferritin, soluble transferrin receptor, and transferrin saturation levels as predictors for 5-year overall survival Figure 2. Receiver operating characteristics (ROC) curve for pretransplant ferritin, soluble transferrin receptor, and transferrin saturation levels as predictors for 5-year overall survival Disclosures: No relevant conflicts of interest to declare.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5228-5228
Author(s):  
Rebecca Connor ◽  
Istvan Molnar ◽  
James Lovato ◽  
Manisha Grover ◽  
David Hurd ◽  
...  

Abstract Transfusional iron overload is common in survivors of acute leukemia and hematopoietic stem cell transplantation and might cause long-term liver dysfunction. Routine evaluation for iron overload in such patients is recommended because excess iron can be readily removed from the body via phlebotomy or chelation. Iron overload might be associated with worse survival after stem cell transplantation in these diseases. We were interested in determining whether levels of the iron binding protein ferritin or the serum transferrin receptor (TfR) were predictive for survival. In a prospective study, we examined the correlation between iron parameters at the time of transplantation and overall survival. Serum ferritin, transferrin saturation, and TfR were measured before preparative regimen on patients who underwent hematopoietic stem cell transplantation between 1999 and 2004 for the diagnosis of aplastic anemia, MDS or acute leukemia (n=79). We used the number of transfusions before transplantation as a measure of iron load. Among these iron markers, serum ferritin correlated the most with the number of transfusions, regardless of remission status. High ferritin (&gt;1,500 ng/ml), low TfR (≤4 μg/ml) and low TfR/log ferritin ratio (≤2) were associated with shorter survival (p=0.005, 0.04, and 0.001 respectively)(Figure 1). Among acute leukemia patients in remission, there was no difference in overall survival between patients with high or low iron markers. Markers of iron excess (serum ferritin &gt;1,500 ng/ml, TfR/log ferritin ratio ≤2) at the time of stem cell transplantation is associated with shorter survival in MDS, aplastic anemia and acute leukemia with active disease. These results demonstrate that knowledge of patient ferritin and TfR levels can aid in risk stratification. The results also suggest that patients with high levels of ferritin may benefit from iron chelation before treatment. Figure 1: Overall Survival based on iron parameters (A) Serum Ferritin (B) Serum Transferrin Receptor (C) TfR (mcg/ml) divided by log ferritin (ng/ml) Figure 1:. Overall Survival based on iron parameters (A) Serum Ferritin (B) Serum Transferrin Receptor (C) TfR (mcg/ml) divided by log ferritin (ng/ml)


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 347-347
Author(s):  
Sara C. Meyer ◽  
Andreas S. Buser ◽  
André Tichelli ◽  
Jakob R. Passweg ◽  
Martin Stern

Abstract Abstract 347 Introduction: Iron overload is frequent in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) due to multiple red blood cell transfusions in the pre- and post-transplant period. Serum ferritin is a routine marker for iron overload. Along with transferrin saturation and soluble transferrin receptor, it was recently shown to strongly impact on survival after HSCT. Reduction of iron overload – e.g. by chelation - might improve the outcome after allogeneic transplantation. To analyze whether patients might benefit from post-transplant interventions aimed at reducing iron overload, we evaluated the impact of iron parameters on survival in a cohort of patients in which complete iron parameters were assessed before and at multiple time-points after transplantation. Methods: We studied 153 consecutive patients undergoing unmanipulated T-cell replete allogeneic transplantation at our center between 2005 and 2009. Among 90 males and 63 females with a median age of 46.5 years (range 18 – 70 years), underlying diseases were AML/MDS (n=87), ALL (n=25), lymphoma/myeloma (n=25), CML/MPN (n=12) and non-malignant (n=4). Donors were HLA-identical (n=78) or one-antigen mismatched (n=2) siblings, or unrelated volunteer donors (n=73). Patients with lymphoma received conditioning with BEAM, fludarabine and single dose total body irradiation (TBI). All other patients were treated with cyclophosphamide and busulfan, or cyclophosphamide and TBI +/− etoposide. Graft-vs-host disease prophylaxis was with Cylosporin A plus either methotrexate or mycophenolate. Serum iron parameters including ferritin, transferrin saturation, transferrin, iron and soluble transferrin receptor (sTfR) were determined before HSCT as well as 3, 6, 12, 24, 36 and 60 months post-transplant. Patients were categorized into groups with high or low iron parameters according to values above or below median at each time-point. Predictors of transplant outcome were further evaluated in multivariable Cox models using disease and stage as covariates. Results: Of the 153 patients, 83 were alive at last contact with a median follow-up of 3.4 years. Ferritin was strongly elevated before HSCT (median 1344 ng/ml, range 16–6507 ng/ml), peaked 3 months post-transplant (median 2508 ng/ml, range 71–9756 ng/ml) and continuously decreased to reach values within the normal range at 5 years (median 242.5 ng/ml, range 28–984ng/ml). Transferrin saturation and iron analogously peaked in the early post-transplant period and subsequently lowered, while transferrin and sTfR increased after an early post-transplant nadir up to 5 years. The post-transplant course of all iron parameters is shown in Fig 1. As demonstrated previously, survival analysis showed a poor survival of patients with a pre-transplant ferritin value above the median (hazard ratio 2.4, p=0.001). Time-stratified landmark survival analysis showed that iron overload (as assessed by ferritin levels above the median at the respective time-point) had a detrimental effect on survival in all periods analyzed (0–6 months p=0.01; 6–12 months p<0.001; 1–2 years p=0.07; and 2–5 years p=0.02. Figure 2). Interestingly, no patient with a ferritin level below the median died more than six months post-transplant. Excess mortality in patients with high ferritin was due to increased transplant related mortality. After adjustment for disease and stage, elevated ferritin values retained their prognostic significance. Analysis of the other iron parameters showed similar trends, but their prognostic value was lower than that of ferritin. Conclusions: Iron overload before HSCT as well as during the post-transplant follow-up confers an increased risk of death. Iron parameters significantly impact on survival during all post-transplant intervals analyzed. Thus, our data suggest that patients may benefit from interventions to reduce iron overload after HSCT. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4029-4029 ◽  
Author(s):  
Flávio Augusto Naoum ◽  
Breno Pannia Esposito ◽  
Milton Arthur Ruiz ◽  
Rodolfo Cancado ◽  
José Carlos Barros

Abstract Nontransferrin-bound iron (NTBI) has been reported shortly after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT), and it is assumed that the appearance of unbound iron in this nontransfusion setting possibly reflects a major disturbance in body iron distribution, which is related mainly to its underutilization due to erythropoiesis suppression. There is a concern that labile plasma iron (LPI), the most toxic fraction of NTBI that includes the redox-active forms of iron, can be involved in the occurrence of toxicity and other complications commonly observed in the early post-HSCT period. Recently, we demonstrated that LPI levels, albeit normal at baseline measurements, increased substantially 48 hours after the start of conditioning in HSCT patients and remained increased until engraftment, when it returned to normal levels (Acta Haematol 2014;131:222-226). Here we provide a more detailed analysis of iron status in HSCT patients by adding determinations of hepcidin and standard iron parameters along with LPI in 25 adult patients undergoing first autologous HSCT following myeloablative conditioning. All iron parameters were determined before the start of conditioning (baseline), on day 0 (before stem cells infusion) and upon documented engraftment (Table). The fast and substantial increase in LPI levels on day 0, indeed reflected a disruption of iron homeostasis by conditioning, that was accompanied by a response in hepcidin and TfS levels. However, reutilization of iron by a restored erythropoiesis upon engraftment lead to a substantial drop in LPI, but not in hepcidin levels, possibly due to the fact that production of hepcidin by the liver is not only modulated by iron loading and erythropoietic activity, but also inflammation. Ferritin baseline levels were already increased and did not change throughout the study. Considering all determinations (baseline, day 0 and engraftment), hepcidin levels correlated positively with ferritin (r=0,43; p=0,01; Figure Panel A) and TfS (r=0,37; p=0,02; Figure Panel B); and LPI correlated positively with TfS (r=4,3; p=0,002; Figure Panel C), although increased LPI levels were observed with normal TfS levels in some patients. A tendency of correlation between hepcidin and LPI was found considering only baseline and day 0 levels (r=0,30; p=0,05; Figure Panel D). These results indicate that LPI reflected better the changes in iron status caused by cytotoxic chemotherapy in HSCT patients, and could serve as a target in the eventuality of chelation therapy in the early period of HSCT. The other iron parameters were probably influenced by inflammation, even upon engraftment, and would not behave as appropriate surrogate markers for increased LPI levels. *LPI levels <0.5μM are considered normal. † p<0,05 in relation to baseline levels. Figure. Correlations between LPI, hepcidin and transferrin saturation levels throughout the study. Figure. Correlations between LPI, hepcidin and transferrin saturation levels throughout the study. Disclosures No relevant conflicts of interest to declare.


1999 ◽  
Vol 45 (12) ◽  
pp. 2191-2199 ◽  
Author(s):  
Anne C Looker ◽  
Mark Loyevsky ◽  
Victor R Gordeuk

Abstract Background: Serum transferrin receptor (sTfR) concentrations are increased in iron deficiency. We wished to examine whether they are decreased in the presence of potential iron-loading conditions, as reflected by increased transferrin saturation (TS) on a single occasion. Methods: We compared sTfR concentrations between 570 controls with normal iron status and 189 cases with increased serum TS on a single occasion; these latter individuals may be potential cases of iron overload. Cases and controls were selected from adults who had been examined in the third National Health and Nutrition Examination Survey (1988–1994) and for whom excess sera were available to perform sTfR measurements after the survey’s completion. Increased TS was defined as &gt;60% for men and &gt;55% for women; normal iron status was defined as having no evidence of iron deficiency, iron overload, or inflammation indicated by serum ferritin, TS, erythrocyte protoporphyrin, and C-reactive protein. Results: Mean sTfR and mean log sTfR:ferritin were ∼10% and 24% lower, respectively, in cases than in controls (P &lt;0.002). Cases were significantly more likely to have an sTfR value &lt;2.9 mg/L, the lower limit of the reference interval, than were controls (odds ratio = 1.8; 95% confidence interval, 1.04–2.37). Conclusion: Our results support previous studies that suggested that sTfR may be useful for assessing high iron status in populations.


2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Michael Karremann ◽  
Eva Neumaier-Probst ◽  
Frank Schlichtenbrede ◽  
Fabian Beier ◽  
Tim H. Brümmendorf ◽  
...  

Abstract Background Revesz syndrome (RS) is an extremely rare variant of dyskeratosis congenita (DKC) with only anecdotal reports in the literature. Methods To further characterize the typical features and natural course of the disease, we screened the English literature and summarized the clinical and epidemiological features of previously published RS cases. In addition, we herein describe the first recorded patient in central Europe. Results The literature review included 18 children. Clinical features are summarized, indicating a low prevalence of the classical DKC triad. All patients experienced early bone marrow failure, in most cases within the second year of life (median age 1.5 years; 95% CI 1.4–1.6). Retinopathy occurred typically between 6 and 18 months of age (median age 1.1 years; 95% CI 0.7–1.5). The incidence of seizures was low and was present in an estimated 20% of patients. The onset of seizures was exclusively during early childhood. The Kaplan–Meier estimate of survival was dismal (median survival 6.5 years; 95% CI 3.6–9.4), and none of the patients survived beyond the age of 12 years. Stem cell transplantation (SCT) was performed in eight children, and after a median of 22 months from SCT four of these patients were alive at the last follow up visit. Conclusion RS is a severe variant of DKC with early bone marrow failure and retinopathy in all patients. Survival is dismal, but stem cell transplantation may be performed successfully and might improve prognosis in the future.


2017 ◽  
Vol 24 (2) ◽  
pp. 123 ◽  
Author(s):  
J. Frazer ◽  
S. Couban ◽  
S. Doucette ◽  
S. Shivakumar

Background Allogeneic hematopoietic stem-cell transplantation (ahsct) is associated with significant morbidity and mortality, but it can cure carefully selected patients with acute myeloid leukemia (aml) in second remission (cr2). In a cohort of patients with aml who underwent ahsct in cr2, we determined the pre-transplant factors that predicted for overall survival (os), relapse, and non-relapse mortality. We also sought to validate the prognostic risk groups derived by Michelis and colleagues in this independent population.Methods In a retrospective chart review, we obtained data for 55 consecutive patients who underwent ahsct for aml in cr2. Hazard ratios were used to describe the independent effects of pre-transplant variables on outcome, and Kaplan–Meier curves were used to assess outcomes in the three prognostic groups identified by Michelis and colleagues.Results At 1, 3, and 5 years post-transplant, os was 60%, 45.5%, and 37.5% respectively. Statistically significant differences in os, relapse mortality, and non-relapse mortality were not identified between the prognostic risk groups identified by Michelis and colleagues. Women were less likely than men to relapse, and a modified European Society for Blood and Marrow Transplantation (mebmt) score of 3 or less was associated with a lower non-relapse mortality.Conclusions The 37.5% 5-year os in this cohort suggests that, compared with other options, ahsct offers patients with aml in cr2 a better chance of cure. Our study supports the use of the mebmt score to predict non-relapse mortality in this population.


2013 ◽  
Vol 19 (3) ◽  
pp. 440-444 ◽  
Author(s):  
Sara C. Meyer ◽  
Alix O’Meara ◽  
Andreas S. Buser ◽  
André Tichelli ◽  
Jakob R. Passweg ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document